Blue Trust’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
Other funds holding NBIX
Blue Trust's NBIX Position: Q3 2026 in Review
Blue Trust increased its Neurocrine Biosciences (NBIX) stake by 13% in Q3 2026, buying an estimated $25.2K and bringing the position to 1,392 shares worth $197K. The position accounts for ﹤0.01% of the portfolio, ranked #769.
Blue Trust first reported a position in NBIX in Q2 2022 and has held it in 17 quarters since. The position peaked at $208K in Q2 2026. 641 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.
- Blue Trust held 1,392 shares of Neurocrine Biosciences worth $197K as of Q3 2026.
- Blue Trust bought 157 Neurocrine Biosciences shares in Q3 2026, an estimated $25.2K.
- Neurocrine Biosciences made up ﹤0.01% of Blue Trust's portfolio in Q3 2026, its #769 holding.
- Blue Trust first reported a position in Neurocrine Biosciences in Q2 2022 and has held it in 17 quarters since.
- Blue Trust's Neurocrine Biosciences position peaked at $208K in Q2 2026.
- 641 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.
Based on Blue Trust's 13F filing for Q3 2026, filed 15 Oct 2026.